---
title: "Mounjaro (tirzepatide), all indications: Access and coverage questions"
description: "Access and coverage questions on Mounjaro (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Access and billing. Questions: What are the NDC numbers for Mounjaro? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/mounjaro/access-and-coverage"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide), all indications: Access and coverage questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)

## Access and billing

<a id="mounjaro-ndc"></a>

### What are the NDC numbers for Mounjaro?

> “MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, 1 multi-dose vial, or 1 Single-Patient-Use KwikPen as follows:
>
> Single-Dose Vial and Prefilled Pen
> Strength	4-pack Single-dose Pen NDC	1-pack Single-dose Vial NDC
> 2.5 mg/0.5 mL	0002-1506-80	0002-1152-01
> 5 mg/0.5 mL	0002-1495-80	0002-1243-01
> 7.5 mg/0.5 mL	0002-1484-80	0002-2214-01
> 10 mg/0.5 mL	0002-1471-80	0002-2340-01
> 12.5 mg/0.5 mL	0002-1460-80	0002-2423-01
> 15 mg/0.5 mL	0002-1457-80	0002-3002-01
> Multi-Dose Vial
> Doses per Vial	Strength	1-pack Multi-dose Vial NDC
> 4 doses of 2.5 mg/0.6 mL	10 mg/2.4 mL (4.17 mg/mL)	0002-4052-11
> 4 doses of 5 mg/0.6 mL	20 mg/2.4 mL (8.33 mg/mL)	0002-4103-11
> 4 doses of 7.5 mg/0.6 mL	30 mg/2.4 mL (12.5 mg/mL)	0002-4210-11
> 4 doses of 10 mg/0.6 mL	40 mg/2.4 mL (16.7 mg/mL)	0002-4304-11
> 4 doses of 12.5 mg/0.6 mL	50 mg/2.4 mL (20.8 mg/mL)	0002-4523-11
> 4 doses of 15 mg/0.6 mL	60 mg/2.4 mL (25 mg/mL)	0002-4612-11
> Single-Patient-Use KwikPen (with four weekly doses)
> Doses per KwikPen	Strength	1-pack Single-Patient-Use KwikPen NDC
> 4 doses of 2.5 mg	10 mg/2.4 mL (4.17 mg/mL)	0002-3466-11
> 4 doses of 5 mg	20 mg/2.4 mL (8.33 mg/mL)	0002-3455-11
> 4 doses of 7.5 mg	30 mg/2.4 mL (12.5 mg/mL)	0002-3444-11
> 4 doses of 10 mg	40 mg/2.4 mL (16.7 mg/mL)	0002-3433-11
> 4 doses of 12.5 mg	50 mg/2.4 mL (20.8 mg/mL)	0002-3422-11
> 4 doses of 15 mg	60 mg/2.4 mL (25 mg/mL)	0002-3411-11”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20is%20a%20clear%2C%20colorless%20to%20slightly%20yellow%20solution,0002%2D3411%2D11)

> “2.5-mg dose NDC: 0002-1506-80; 5-mg dose NDC: 0002-1495-80”

Source: [MOUNJARO: Getting Started, Dosing & Prescribing, captured 2026-11-12](https://mounjaro.lilly.com/hcp/getting-patients-started#:~:text=2.5%2Dmg%20dose%20NDC%3A%200002%2D1506%2D80%3B%205%2Dmg%20dose%20NDC%3A%200002%2D1495%2D80)

## Related pages
- [Medical information: Mounjaro (tirzepatide): All indications](https://www.evicenter.com/medical-information/mounjaro)
- [Indication](https://www.evicenter.com/medical-information/mounjaro/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/mounjaro/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/mounjaro/safety)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/mounjaro/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/mounjaro/storage-and-supply)
